<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706939</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-1050</org_study_id>
    <nct_id>NCT01706939</nct_id>
  </id_info>
  <brief_title>The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer</brief_title>
  <official_title>The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Biodesign Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to directly compare a reduced radiation dose to the standard of care in
      HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two
      groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are
      non-inferior to standard dose CRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized Phase III study comparing two doses of definitive radiation therapy
      given with induction and concurrent chemotherapy in HPV-positive oropharynx, unknown primary
      or nasopharynx cancer. Eligible, consented and registered patients will receive three cycles
      of Docetaxel Cisplatin and 5-FU (TPF) induction chemotherapy. After 3 cycles, the patients
      will be assessed for clinical, radiographic and pathologic response to TPF. Patients with a
      clinical or radiographic CR or PR will be randomized on the second phase of this study, where
      patients will undergo a 2:1 randomization to reduced (5600 cGy) or standard (7000 cGy) dose
      radiotherapy with weekly Carboplatin. Patients not meeting the response criteria will be
      treated with standard dose CRT. Patients not completing 3 cycles TPF for reasons of toxicity,
      progressive disease, choice, or other medical necessity will be treated with standard dose
      CRT or surgery depending on their primary site and overall medical condition and followed for
      survival. Toxicity will be assessed by Symptom scores, QOL and SAE monitoring. The primary
      end point of the trial is equivalent local regional control and PFS at 3 years. Patients will
      be followed for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>at 3 years</time_frame>
    <description>To determine the comparative rate of progression free survival (PFS) at 3 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of local-regional control</measure>
    <time_frame>at 3 years</time_frame>
    <description>To determine the comparative rate of local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at 5 years</time_frame>
    <description>To determine Overall Survival (OS) 5 years treated with reduced or standard dose CRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity of CRT</measure>
    <time_frame>at 5 years</time_frame>
    <description>To compare acute toxicity in patients treated with reduced or standard dose CRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers predictive of failure</measure>
    <time_frame>at 5 years</time_frame>
    <description>To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Squamous Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Reduced Dose Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Reduced Dose Radiation</intervention_name>
    <description>Reduced Dose Radiation (5600 cGy) dose radiotherapy</description>
    <arm_group_label>Reduced Dose Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Dose Radiation</intervention_name>
    <description>Standard Dose Radiation (7000 cGy) dose radiotherapy</description>
    <arm_group_label>Standard Dose Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Day 1, every 21 days ( + 2 days)</description>
    <arm_group_label>Reduced Dose Radiation</arm_group_label>
    <arm_group_label>Standard Dose Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed squamous cell
             carcinoma of the oropharynx, unknown primary, or nasopharynx that is HPV positive as
             determined by PCR and p16 positive as determined by IHC. Tissue from the primary site
             must be available for biomarker studies. PCR and IHC must be performed in the central
             laboratory (Zhang, MSSM)

          -  Stage 3 or 4 disease without evidence of distant metastases.

          -  At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by
             RECIST 1.1 criteria.

          -  Age &gt; 18 years.

          -  No previous surgery, radiation therapy or chemotherapy for SSCHN (other than biopsy or
             tonsillectomy) is allowed at time of study entry.

          -  ECOG performance status of 0 or 1.

          -  No active alcohol addiction (as assessed by medical caregiver and defined as at least
             6 months without activity).

          -  Participants must have adequate bone marrow, hepatic and renal functions as defined in
             the protocol.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Patients with Gilbert's Disease and absent hepatic pathology by history and clinical
             assessment maybe treated on study with bilirubins &gt; the ULN for the institution if
             other liver function studies are within the normal range

        Exclusion Criteria:

          -  Pregnant or breast feeding women, or women and men of childbearing potential not
             willing to use adequate contraception while on treatment and for at least 3 months
             thereafter.

          -  Previous or current malignancies at other sites, with the exception of adequately
             treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin,
             thyroid cancer, or other cancer curatively treated by surgery and with no current
             evidence of disease for at least 5 years.

          -  Symptomatic peripheral neuropathy ≥ grade 2 by NCI Common Terminology Criteria
             (NCI-CTC) version 4.

          -  Symptomatic altered hearing &gt; grade 2 by NCI-CTCv4 criteria.

          -  Other serious illnesses or medical conditions including but not limited to:

               1. Unstable cardiac disease despite treatment, myocardial infarction within 6 months
                  prior to study entry

               2. History of significant neurologic or psychiatric disorders including dementia or
                  seizures

               3. Active clinically significant uncontrolled infection

               4. Active peptic ulcer disease defined as unhealed or clinically active

               5. Hypercalcemia

               6. Active drug addiction including alcohol, cocaine or intravenous drug use defined
                  as occurring within the 6 months preceding diagnosis

               7. Chronic Obstructive Pulmonary Disease, defined as being associated with a
                  hospitalization for pneumonia or respiratory decompensation within 12 months of
                  diagnosis. This does not include obstruction from tumor

               8. Autoimmune disease requiring therapy, prior organ transplant, or HIV infection

               9. Interstitial lung disease

              10. Hepatitis C (test required)

          -  Patients that have experienced an involuntary weight loss of more than 25% of their
             body weight in the 2 months preceding study entry.

          -  Concurrent treatment with any other anticancer therapy.

          -  Participation in an investigational therapeutic drug trial within 30 days of study
             entry.

          -  Active smoking within the past 20 years with a cumulative Pack Year history of &gt; 20
             Pack Years or active smoking (Defined as &gt; 1 cigarette per day) within the last 2
             years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall Posner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.</citation>
    <PMID>21969503</PMID>
  </reference>
  <reference>
    <citation>Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008 Feb 1;26(4):612-9. doi: 10.1200/JCO.2007.14.1713.</citation>
    <PMID>18235120</PMID>
  </reference>
  <reference>
    <citation>Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M, Lindquist D, Ramqvist T, Lindholm J, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E, Dalianis T. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009 Jul 15;125(2):362-6. doi: 10.1002/ijc.24339.</citation>
    <PMID>19330833</PMID>
  </reference>
  <reference>
    <citation>Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 1998 Jan 1;58(1):5-13.</citation>
    <PMID>9426048</PMID>
  </reference>
  <reference>
    <citation>Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004 Nov;78(21):11451-60. Review.</citation>
    <PMID>15479788</PMID>
  </reference>
  <reference>
    <citation>Psyrri A, DeFilippis RA, Edwards AP, Yates KE, Manuelidis L, DiMaio D. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res. 2004 May 1;64(9):3079-86.</citation>
    <PMID>15126344</PMID>
  </reference>
  <reference>
    <citation>Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006 Feb 10;24(5):736-47. Epub 2006 Jan 9.</citation>
    <PMID>16401683</PMID>
  </reference>
  <reference>
    <citation>Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.</citation>
    <PMID>20530316</PMID>
  </reference>
  <reference>
    <citation>Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000 May 3;92(9):709-20.</citation>
    <PMID>10793107</PMID>
  </reference>
  <reference>
    <citation>Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol. 2006 Dec 20;24(36):5623-5.</citation>
    <PMID>17179099</PMID>
  </reference>
  <reference>
    <citation>Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002 Oct;8(10):3187-92.</citation>
    <PMID>12374687</PMID>
  </reference>
  <reference>
    <citation>Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Apr 20;27(12):1992-8. doi: 10.1200/JCO.2008.20.2853. Epub 2009 Mar 16.</citation>
    <PMID>19289615</PMID>
  </reference>
  <reference>
    <citation>Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006 Dec 20;24(36):5630-6.</citation>
    <PMID>17179101</PMID>
  </reference>
  <reference>
    <citation>Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M, Forastiere AA. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol. 2007 Sep 1;25(25):3971-7.</citation>
    <PMID>17761982</PMID>
  </reference>
  <reference>
    <citation>Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9. doi: 10.1093/jnci/djn011. Epub 2008 Feb 12.</citation>
    <PMID>18270337</PMID>
  </reference>
  <reference>
    <citation>Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008 Jul 1;26(19):3138-46. doi: 10.1200/JCO.2007.12.7597. Epub 2008 May 12.</citation>
    <PMID>18474879</PMID>
  </reference>
  <reference>
    <citation>Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010 Sep 20;28(27):4142-8. doi: 10.1200/JCO.2010.29.2904. Epub 2010 Aug 9.</citation>
    <PMID>20697079</PMID>
  </reference>
  <reference>
    <citation>Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11.</citation>
    <PMID>21233014</PMID>
  </reference>
  <reference>
    <citation>Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May;22(5):1071-7. doi: 10.1093/annonc/mdr006. Epub 2011 Feb 11.</citation>
    <PMID>21317223</PMID>
  </reference>
  <reference>
    <citation>Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008 Jul 20;26(21):3582-9. doi: 10.1200/JCO.2007.14.8841. Epub 2008 Jun 16.</citation>
    <PMID>18559875</PMID>
  </reference>
  <reference>
    <citation>Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8.</citation>
    <PMID>12506176</PMID>
  </reference>
  <reference>
    <citation>Forastiere A, Maor M, Weber R, Pajak, T, Glisson B, Trotti A, Ridge J, et al. Long term results of Intergroup RTOG 91-11: A Phase III trial to preserve the larynx - Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proceedings of the American Society of Clinical Oncology. 2006:5517.</citation>
  </reference>
  <reference>
    <citation>Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71. Erratum in: Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):569.</citation>
    <PMID>11483325</PMID>
  </reference>
  <reference>
    <citation>Taylor SG 4th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994 Feb;12(2):385-95.</citation>
    <PMID>8113846</PMID>
  </reference>
  <reference>
    <citation>Best SR, Ha PK, Blanco RG, Saunders JR Jr, Zinreich ES, Levine MA, Pai SI, Walker M, Trachta J, Ulmer K, Murakami P, Thompson R, Califano JA, Messing BP. Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. Head Neck. 2011 Dec;33(12):1727-34. doi: 10.1002/hed.21657. Epub 2011 Jan 18.</citation>
    <PMID>21246640</PMID>
  </reference>
  <reference>
    <citation>Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.</citation>
    <PMID>19897418</PMID>
  </reference>
  <reference>
    <citation>Agoston ES, Robinson SJ, Mehra KK, Birch C, Semmel D, Mirkovic J, Haddad RI, Posner MR, Kindelberger D, Krane JF, Brodsky J, Crum CP. Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010 Jul;134(1):36-41. doi: 10.1309/AJCP1AAWXE5JJCLZ.</citation>
    <PMID>20551264</PMID>
  </reference>
  <reference>
    <citation>Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck. 2011 Nov;33(11):1622-7. doi: 10.1002/hed.21650. Epub 2010 Dec 28.</citation>
    <PMID>21990227</PMID>
  </reference>
  <reference>
    <citation>Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, Woolgar JA, Helliwell TR, Triantafyllou A, Robinson M, Sloan P, Harvey-Woodworth C, Sisson D, Shaw RJ. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011 Oct 1;17(19):6262-71. doi: 10.1158/1078-0432.CCR-11-0388.</citation>
    <PMID>21969383</PMID>
  </reference>
  <reference>
    <citation>Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010 Feb 15;16(4):1226-35. doi: 10.1158/1078-0432.CCR-09-2350. Epub 2010 Feb 9.</citation>
    <PMID>20145161</PMID>
  </reference>
  <reference>
    <citation>Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 7;104(12):1896-905. doi: 10.1038/bjc.2011.171.</citation>
    <PMID>21654689</PMID>
  </reference>
  <reference>
    <citation>Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008 Jul 1;26(19):3128-37. doi: 10.1200/JCO.2007.12.7662. Epub 2008 May 12.</citation>
    <PMID>18474878</PMID>
  </reference>
  <reference>
    <citation>Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, Panizza B, Coman S, McFarlane D, Coman W. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011 Dec;33(12):1675-82. doi: 10.1002/hed.21655. Epub 2011 Jan 14.</citation>
    <PMID>22076976</PMID>
  </reference>
  <reference>
    <citation>Riemer AB, Keskin DB, Zhang G, Handley M, Anderson KS, Brusic V, Reinhold B, Reinherz EL. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem. 2010 Sep 17;285(38):29608-22. doi: 10.1074/jbc.M110.126722. Epub 2010 Jul 8.</citation>
    <PMID>20615877</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Marshall Posner</investigator_full_name>
    <investigator_title>Director, Head and Neck Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Reduced radiotherapy</keyword>
  <keyword>Randomization, Phase III</keyword>
  <keyword>Reduced radiation therapy</keyword>
  <keyword>head and neck</keyword>
  <keyword>oropharynx</keyword>
  <keyword>unknown primary (cervical lymph nodes)</keyword>
  <keyword>nasopharynx primary</keyword>
  <keyword>HPV</keyword>
  <keyword>p16</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>randomized trial should not be shared until trial is over.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

